| Document |
Document Title |
|
JP2024512710A |
The present invention provides 5-benzylimidazole compounds represented by formula I, and methods for their preparation and uses. The compound of formula I and its pharmaceutically acceptable salts are degraded in plasma and release pharm...
|
|
JP7450916B2 |
To provide a surface anesthetic having a great pain relieving effect.A surface anesthetic contains lidocaine, propitocaine, isopropyl alcohol, and geraniol. The content of geraniol is 0.000001-2 mass% in the surface anesthetic.SELECTED D...
|
|
JP2024511369A |
A conjugate formed between an anesthetic compound and a peptide component having the following amino acid sequence: W-Lys-X1-Ser-UX2-Y During the ceremony, W,X1,U,X2, and Y are as defined herein, as well as regioisomers, stereoisomers, a...
|
|
JP7446109B2 |
A hydrophilic silicone, compositions comprising the same, and articles comprising the same are shown and described herein. The hydrophilic silicone is an ionically modified silicone compound wherein the compound comprises a zwitterionic ...
|
|
JP7444995B2 |
The present invention provides highly bioavailable and stable edible, inhalable, soluble and drinkable pharmaceutical grade ultrafine active pharmaceutical ingredients having 99% purity, and methods for their production.
|
|
JP7443358B2 |
Neuroactive steroid anaesthetic agents, methods for their preparation and compositions comprising the same are disclosed. Also provided are scaled up and/or GMP methods for preparing neuroactive steroids, such as alfaxalone, alfadolone a...
|
|
JP2024510035A |
The present invention provides an oral mucosal film composition comprising a therapeutically effective amount of solid epinephrine particles having a particle size ranging from about 0.01 μm to about 100 μm; and a pharmaceutically acce...
|
|
JP2024028525A |
[Problem] The present invention provides an excellent method that causes less frictional irritation when used on diseased areas etc. in a state impregnated with a medicinal solution, and is sufficiently dispersed by water flow from a flu...
|
|
JP7441556B2 |
The present invention relates to a drug delivery composition using crosslinked hyaluronic acid, a manufacturing method therefor, and a pharmaceutical composition comprising the drug delivery composition and a drug and having a desired re...
|
|
JP7442023B1 |
The object of the present invention is to develop a new dental treatment that can alleviate patient complaints, especially discomfort around the oral cavity, that can occur after treatment when a dental local anesthetic is administered t...
|
|
JP2024508602A |
The present invention provides a multilayer oral cavity comprising first and second matrix layers, each containing at least one polymer, and a separation layer located between the first matrix layer and the second matrix layer. The prese...
|
|
JP2024508603A |
The present invention relates to an oral thin film comprising at least one layer containing at least one polyvinyl alcohol and tris(hydroxymethyl)aminomethane, and the use of such an oral thin film as a medicament. [Selection diagram] Fi...
|
|
JP2024506191A |
The present invention relates to methods of preparing topical pharmaceutical compositions, pharmaceutical compositions prepared by the method, topical pharmaceutical compositions, and uses and methods comprising the present pharmaceutica...
|
|
JP2024018959A |
An object of the present invention is to provide an external preparation composition containing a medicinal ingredient and capable of forming a film having excellent durability and moisture resistance. [Solution] The following ingredient...
|
|
JP2024505227A |
Disclosed herein is a composition for treating post-surgical pain comprising an aqueous carrier; a lipid phase comprising an anesthetic agent, the lipid phase being dispersed within the aqueous carrier. In certain embodiments, the aqueou...
|
|
JP7427259B2 |
The present invention provides methods for determining the selectivity of an anesthetic for an anesthetic-sensitive receptor by determining the molar water solubility of the anesthetic. The invention further provides methods for modulati...
|
|
JP2024504518A |
The present invention provides a GABAA receptor agonist phenol derivative that has a novel structure, has better efficacy, can effectively reduce side effects, and is more clinically safe. The present invention relates to a compound repr...
|
|
JP2024012412A |
The present invention provides methods that help produce local or regional anesthesia or analgesia within neural tissue in a subject. A method comprises administering to a nerve an effective amount of a compound of formula (I) or a pharm...
|
|
JP2024008319A |
[Problem] To provide a packaging bag for a patch that can reduce the amount of aluminum used, have high barrier properties, and prevent volatilization and deterioration of active ingredients contained in the patch, and a patch packaging ...
|
|
JP2024008963A |
Injectable compositions and methods for treating skin to improve hydration, elasticity, and/or texture are provided. The above problems are solved by a composition based on a crosslinked hyaluronic acid matrix made using low molecular we...
|
|
JP2024500638A |
The present invention provides topical administration, topical administration, parenteral administration, comprising the compounds of bupivacaine glyceryl dilauryl fumarate, or bupivacaine glyceryl dilauryl succinate, or bupivacaine glyc...
|
|
JP2024001196A |
The present invention provides an anesthetic composition for locally administering a local anesthetic to a subject in need thereof. The anesthetic composition has a lipid-based complex prepared by hydrating a lipid cake containing a loca...
|
|
JP7410036B2 |
The present invention provides a crystalline form of a benzodiazepine derivative hydrochloride of Formula I or its ethanolate, wherein R is methyl or ethyl. The present invention also provides a method of preparing the crystal form of th...
|
|
JP2023553204A |
Drug composition in a solid drug matrix formulation containing clonidine, midazolam, and fentanyl. The amount of drug contained in the solid drug matrix is sufficient to induce sedation for clinical procedures. When administered orally, ...
|
|
JP2023168340A |
To provide topical formulations of muscarinic M1 receptor antagonists, such as pirenzepine, for treatment of peripheral neuropathies.A topical formulation comprises (i) a muscarinic acetylcholine receptor antagonist or a salt or derivati...
|
|
JP2023168587A |
To provide formulations of nanostructured gels for increased agent loading and adhesion.A gel formulation has been developed which provides high loading, e.g., between about 5% wt./wt. agent/total gel weight and about 50% wt./wt. agent/t...
|
|
JP2023547222A |
The present invention relates to pharmaceutical compositions comprising a liquid oil, a pharmaceutically acceptable gelling agent, a pharmaceutically acceptable stabilizer, and a pharmaceutically active ingredient. Said pharmaceutical co...
|
|
JP7376520B2 |
There is provided a controlled-release antibiotic socket for securely holding an implantable medical device that is made from: at least one film having at least one polymer layer, where the at least one film is formed into the socket; at...
|
|
JP7372356B2 |
The present invention relates to an oral thin film comprising at least one polymer and at least one pharmaceutically active agent, wherein the concentration of the at least one pharmaceutically active agent in the oral thin film is great...
|
|
JP7366916B2 |
Provided is an anesthetic composition for locally administering a local anesthetic agent to a subject in need thereof. The anesthetic composition has a lipid based complex prepared by hydrating a lipid cake containing a local anesthetic ...
|
|
JP2023542784A |
The present invention relates to novel combination therapies for controlling and alleviating pain. More particularly, the present invention relates to a novel long-acting pharmaceutical combination in parenteral dosage form that can be a...
|
|
JP2023139249A |
To provide hyaluronic acid and silk protein fragments based biocompatible tissue fillers.A biocompatible tissue filler comprises silk protein or silk protein fragments (SPFs), hyaluronic acid (HA), and an anesthetic agent. A portion of t...
|
|
JP7355326B2 |
Provided is a pharmaceutical agent for enhancing absorption efficiency of a drug through the mucosal epithelial layer. A pharmaceutical agent for transmucosal administration comprises as an active ingredient a drug compound to which a po...
|
|
JP2023139260A |
To provide compositions for preventing or treating muscle conditions such as muscle damage, injury, or atrophy.Compositions comprise a prostaglandin E2 (PGE2) compound and a myotoxin. The PGE2 compound is selected from the group consisti...
|
|
JP7346712B2 |
The present invention provides a pharmaceutical composition containing betamethasone valerate, which has satisfactory formulation stability. The pharmaceutical composition comprises at least (A) betamethasone valerate and (B) at least on...
|
|
JP2023539022A |
The present invention provides a method for producing sulfaprodil lyophilized powder injection, as well as its products and uses. Specifically, the method of the present invention includes the following steps. Injecting sulfaprodil for i...
|
|
JP7340023B2 |
The present disclosure relates to compounds of formula (AI), (I), (AII), and (II), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, a pharmaceutical composition comprising a compound of formula (AI), (I)...
|
|
JP2023123878A |
To provide neuroactive steroids for use in preventing and treating CNS-related conditions, compositions comprising the neuroactive steroids, and methods of treating CNS-related disorders.Provided herein are 19-nor C3, 3-disubstituted ste...
|
|
JP2023537087A |
The present application relates to compounds with antidepressant, anesthetic, analgesic, cognitive function improving, pulmonary protection, prevention or treatment of amyotrophic lateral sclerosis, or prevention or treatment of complex ...
|
|
JP2023118586A |
To provide a biological information monitor that can reduce burden on a doctor when administering anesthetics, and a display method for the biological information monitor.A biological information monitor includes: a corrected MAC (Minimu...
|
|
JP7328254B2 |
The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof:which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegene...
|
|
JP2023534556A |
Specifically, the present invention uses benzyl acetate, which is inexpensive and readily available, as a raw material and produces an optically pure intermediate ((5S,6R)-5,6-dihydroxycyclohexa-1,3-dienyl)methyl by biological fermentati...
|
|
JP7320852B2 |
A method for continuously processing at least two liquid feed streams is provided. A system for continuously processing at least two liquid feed streams is also provided.
|
|
JP2023533421A |
The present invention relates to a delivery contact lens device for delivering cargo molecules. The device comprises cargo molecules and a nanocomposite comprising hydrophilic polymer domains, hydrophobic polymer domains, aqueous pores, ...
|
|
JP7316214B2 |
The present invention relates to the field of anti-viral active agents, particularly to salts, more particularly to a maleate salt of the free base of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[
4-(2-pyridinyl)-phenyl]-a...
|
|
JP7312822B2 |
The present invention provides an alginic acid-based injectable hydrogel system for labeling an accurate position of a disease lesion and effectively delivering a drug to a target region. The formulation of the present invention can make...
|
|
JP2023529825A |
[wrap up] Kind Code: A1 Disclosed and described are α-RgIA4 peptide analogs, compositions comprising them, and methods for their treatment and use. For example, an α-RgIA4 peptide analog can include a recognition finger region configur...
|
|
JP2023094485A |
To provide a poultice in which the adhesive force of a paste layer to an adherend is strengthened.A poultice comprises a support layer, a paste layer, and a release liner layer, where the paste layer includes a composition (paste composi...
|
|
JP2023094484A |
To provide a poultice in which the adhesive force of a paste layer to an adherend is strengthened.A poultice comprises a support layer, a paste layer, and a release liner layer, where the paste layer includes a composition (paste composi...
|
|
JP2023528644A |
Antidepressant, amelioration of anxiety and post-traumatic stress syndrome, anesthesia, analgesia, improvement of cognitive function, lung protection, prevention or treatment of amyotrophic lateral sclerosis, or prevention or treatment o...
|
